Company profile
HOME - SiSaf Ltd
SiSaf delivers on the promise of RNA therapeutics with Bio-Courier technology.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
RP04AP01 | Transaction MzQ0MTg4NTE3MGFkaXF6a2N4
Published 07 Nov 2024 08:35
CS01 | Transaction MzQ0MTg4Nzg5NGFkaXF6a2N4
Published 04 Nov 2024 12:29
AA | Transaction MzQzNjQwMjk2MGFkaXF6a2N4 | Paper/PDF filed
Published 20 Sep 2024 11:10
AP01 | Transaction MzIxMTY2NzI5N2FkaXF6a2N4 | Paper/PDF filed
Published 19 Nov 2024 02:09
Company registered at Companies House
1 Jan 2021 to 30 Jun 2021
**Background.** It has emerged through the COVID-19 pandemic outbreak that there is a significant need to have disease control tools that can be rapidly deployed in an emergency situation and an increased need to be able to rapidly repurpose existing drugs for new indications for a disease syndrome that induces a range of disease outcomes from mild to ver...
1 Jun 2019 to 30 Apr 2022
To develop formulations to reduce the frequency of intravitreal injections with targeting and controlled release of known drugs for treatment of age related macular degeneration to reduce and prevent blindness.
1 Jan 2019 to 30 Jun 2020
To develop a continuous production chemical engineering process for a proprietary nanoparticle drug delivery system.
1 Jul 2016 to 30 Jun 2018
To develop eye drops using revolutionary new nanotechnology to overcome drug delivery challenges in ophthalmology to treat, cure and prevent eye disease ( including eye removal, transplants and blindness in children and adults) with enhanced outcomes.
